Management

MICHAEL HEFFERNAN

Founder, President, CEO

Michael Heffernan is the Founder, President and CEO of Collegium Pharmaceutical, Inc. He has more than 25 years of experience in the pharmaceutical and related healthcare industries. He was previously the Founder, President and CEO of Onset Dermatologics, a dermatology focused company that was spun out of Collegium to create PreCision Dermatology and was sold to Valeant (2014). Michael held prior positions as Co-Founder, President and CEO of Clinical Studies Ltd., a pharmaceutical contract research organization that was sold to PhyMatrix Corp and later served as President and CEO of PhyMatrix. Michael began his career at Eli Lilly and Company and served in numerous sales and marketing roles. He has also been an advisor and Investor in a number of healthcare companies. His past board memberships include; TyRx (sold to Medtronic), Cornerstone Therapeutics (sold to Chiesi), Ocata (sold to Astellas), and PreCision Dermatology. Michael is currently the Chairman of the board for Veloxis Pharmaceuticals (OMX:VELO) and serves on the board for Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX). Michael earned his B.S. Degree in Pharmacy from the University of Connecticut and is a Registered Pharmacist.

PAUL BRANNELLY

Executive Vice President and Chief Financial Officer

Paul Brannelly joined Collegium Pharmaceutical in February 2015 as Executive Vice President and Chief Financial Officer. Prior to joining Collegium, Paul held senior financial management positions for both publicly held and privately held companies, gaining significant experience raising capital, executing growth strategies and mergers and acquisitions. Paul most recently served as Senior Vice President, Finance & Administration, and Treasurer of Karyopharm Therapeutics Inc., a publicly traded, clinical-stage pharmaceutical company. Prior to Karyopharm, Paul served as Vice President Finance, Treasurer, and Secretary for Verastem, Incorporated, a publicly traded biotechnology company. Earlier in his career, Paul was Chief Financial Officer of Longwood Fund, a healthcare dedicated venture capital fund, and also held senior financial management roles with Sirtris Pharmaceuticals (acquired by GlaxoSmithKline), CombinatoRx and Dyax. With over 15 years in the biopharmaceutical industry, Paul has raised more than $750 million in public and private capital. Paul holds a Bachelors in Business Administration in Accounting from University of Massachusetts at Amherst and was a Certified Public Accountant.

BARRY S. DUKE

Executive Vice President and Chief Commercial Officer

Barry Duke joined Collegium Pharmaceutical in March 2015 as Executive Vice President and Chief Commercial Officer. Prior to joining Collegium, Barry held senior sales and marketing positions at several pharmaceutical companies where he was responsible for building teams and leading commercial initiatives. Most recently, Barry served as Vice President of Sales and Marketing for Sanofi, Inc. (formerly Genzyme), US Biosurgery Division where he held the commercial lead role for the $400M US Orthopedic business. Prior to this role with Sanofi (post acquisition), Barry held senior sales roles with Genzyme where he was responsible for leading the 155 person sales force as well as the managed markets, sales training, and commercial operations teams. With more than 30 years of experience in pharmaceutical marketing and sales, Barry has also held various commercial positions at Enzon Pharmaceuticals, Elan, the Liposome Co., and other pharmaceutical companies throughout his career. Barry has broad experience across multiple therapeutic areas.Barry received his Bachelor of Arts degree in Biology from the University of Virginia.

ALISON B. FLEMING, Ph.D.

Chief Technology Officer

Dr. Alison Fleming joined Collegium Pharmaceutical in 2002, shortly after completing her Ph.D. in the School of Chemical and Biomolecular Engineering at Cornell University. Prior to joining Collegium, her academic research focused on implantable drug delivery systems for cancer therapy. Dr. Fleming is an inventor on several United States Patents and pending patent applications, and has authored numerous scientific publications and poster presentations in the field of novel drug delivery systems. In 2001 she was the recipient of the Jorge Heller Journal of Controlled Release Outstanding Paper Award. She received her B.S. degree in Chemical Engineering from the University of Massachusetts, Amherst.